Immunotherapy Esophagus Cancer

1

Review clinical trials related to Immunotherapy Esophagus Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (ESCC)

Participants needed: 93
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Fuzhou General HospitalUpdated: Feb 7, 2024Locations: 1
Eligibility criteria

Histologically confirmed localized ESCC that is suitable for cCRT, including: st... [+8]

A history of fistula caused by primary tumor invasion; [+10]